Legend Biotech (LEGN) Other Non-Current Liabilities (2020 - 2025)
Legend Biotech (LEGN) posted Other Non-Current Liabilities of $8.0 million for Q4 2025, down 1.54% on a QoQ basis from $8.1 million in Q3 2025, and up 31.15% year-over-year from $6.1 million in Q4 2024.
Legend Biotech (LEGN) Other Non-Current Liabilities (2020 - 2025) Analysis & Trends
Legend Biotech's Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $8.0 million for Q4 2025.
- Quarterly Other Non-Current Liabilities rose 31.15% year-over-year to $8.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.0 million (up 31.15% YoY) and the FY2025 annual result came in at $8.0 million, up 31.15% from the prior year.
- Other Non-Current Liabilities was $8.0 million for Q4 2025 at Legend Biotech, down from $8.1 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $8.1 million in Q3 2025 and bottomed at $554.0 in Q1 2021.
- A 5-year average of $2.7 million and a median of $356000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 64159.93% — and 2023, when it sank 99.27%.
- Legend Biotech's Other Non-Current Liabilities stood at $396000.0 in 2021, then jumped by 1834.09% to $7.7 million in 2022, then sank by 99.27% to $56000.0 in 2023, then surged by 10792.86% to $6.1 million in 2024, then jumped by 31.15% to $8.0 million in 2025.
- Business Quant data shows LEGN's Other Non-Current Liabilities at $8.0 million in Q4 2025, $8.1 million in Q3 2025, and $6.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Legend Biotech | 8.26 Bn | 7.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.00 Mn |
| Sep 30, 2025 | 8.13 Mn |
| Jun 30, 2025 | 6.89 Mn |
| Mar 31, 2025 | 6.06 Mn |
| Dec 31, 2024 | 6.10 Mn |
| Sep 30, 2024 | 27,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 56,000.00 |
| Sep 30, 2023 | 119,000.00 |
| Jun 30, 2023 | 152,000.00 |
| Mar 31, 2023 | 224,000.00 |
| Dec 31, 2022 | 7.66 Mn |
| Mar 31, 2022 | 356,000.00 |
| Dec 31, 2021 | 396,000.00 |
| Sep 30, 2021 | 991,000.00 |
| Jun 30, 2021 | 554.00 |
| Mar 31, 2021 | 554.00 |
| Dec 31, 2020 | 2.05 Mn |
| Sep 30, 2020 | 2,033.00 |